1h Free Analyst Time
The thyroid gland disorder treatment market is forecasted to grow by USD 848.5 million during 2023-2028, accelerating at a CAGR of 5.01% during the forecast period. The report on the thyroid gland disorder treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rise in thyroid treatment awareness programs globally, increasing demand for levothyroxine, and growing patient population with iodine deficiency.
The thyroid gland disorder treatment market is segmented as below:
By Type
- Hypothyroidism
- Hyperthyroidism
By Distribution Channel
- Offline
- Online
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the thyroid gland disorder treatment market covers the following areas:
- Thyroid gland disorder treatment market sizing
- Thyroid gland disorder treatment market forecast
- Thyroid gland disorder treatment market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global thyroid gland disorder treatment market: Abbott Laboratories, AbbVie Inc., Alvogen Iceland ehf, Amgen Inc., Exelixis Inc., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, IBSA Institute Biochimique SA, JEROME STEVENS PHARMACEUTICALS INC., Lannett Co. Inc., Lupin Ltd., Mayne Pharma Group Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Piramal Enterprises Ltd., RLC Labs Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and Viatris Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is rising focus on emerging economies."
According to the report, one of the major drivers for this market is the rise in thyroid treatment awareness programs globally.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AbbVie Inc.
- Alvogen Iceland ehf
- Amgen Inc.
- Exelixis Inc.
- Fresenius SE and Co. KGaA
- GlaxoSmithKline Plc
- IBSA Institute Biochimique SA
- JEROME STEVENS PHARMACEUTICALS INC.
- Lannett Co. Inc.
- Lupin Ltd.
- Mayne Pharma Group Ltd.
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Piramal Enterprises Ltd.
- RLC Labs Inc.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Viatris Inc.